[Vip in human neonates and infants. As measured by radioimmunoassay and radioreceptorassay (author's transl)].
The Vasoactive Intestinal Peptide (VIP) was assayed in the gut of human neonates and premature infants immediately after death or surgery. In these conditions, values ranged between 150 and 740 ng/g of bioled tissue. The implication of VIP in Vermer-Morrison syndrome is further assessed by the correlation between clinical symptomatology and plasma VIP levels. The immunoassayable VIP (IA-VIP) extracted from normal gut or tumor is shown to fully interact with specific receptor for VIP in liver. This fact suggests the biological potency of IA-VIP.
D001681:Biological Assay; D003106:Colon / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000032:analysis*; D006801:Humans; D007082:Ileum / Q000378:metabolism; D007231:Infant, Newborn; D007234:Infant, Premature; D007422:Intestines / Q000032:analysis*; D007583:Jejunum / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D011863:Radioimmunoassay / Q000379:methods; D011956:Receptors, Cell Surface; D014660:Vasoactive Intestinal Peptide / Q000032:analysis* / Q000097:blood
D005768:Gastrointestinal Hormones; D011956:Receptors, Cell Surface; D014660:Vasoactive Intestinal Peptide
VIP plasmatique et intestinal de l'enfant. Dosage par radio-immunologie et par radio-récepteurs.